Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Hypercholesterolaemia
Interventions: laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Sun City West, Arizona • Gardena, California • Lomita, California + 22 more

Conditions: Alcohol Use Disorder
Interventions: Virtual Practice Facilitation with e-Learning, Virtual Practice Facilitation without e-Learning; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Older Aged Adults; Balance
Interventions: Tai-chi prime (TCP); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: La Crosse, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Hepatitis C, Chronic
Interventions: midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more

Conditions: Healthy
Interventions: Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day to 49 Years
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 119
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 54 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 80
States / cities: Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more

Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions: Azacitidine, Lenalidomide, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 65 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more

Conditions: Pain
Interventions: Adductor Canal Block, Periarticular Injection, Ropivacaine, Bupivacaine; Procedure · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Herceptin, NeuVax vaccine, GM-CSF; Drug
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 29
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more

Conditions: Stroke
Interventions: High Frequency rTMS, Sham rTMS; Device
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Disease Group, Control Group; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
Interventions: Rosuvastatin (Crestor), Ezetimibe, Simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Pneumonia
Interventions: Murepavadin, Two anti-pseudomonal antibiotics; Drug
Lead sponsor: Polyphor Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina

Conditions: Cataract
Interventions: nepafenac 0.3%, ketorolac; Drug
Lead sponsor: MDbackline, LLC; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Laguna Hills, California • Edgewood, Kentucky

Conditions: Advanced Solid Tumor Cancer
Interventions: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more

Conditions: Non-Small Cell Lung Cancer
Interventions: CDX-1401, MPDL3280A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Knee Osteoarthritis
Interventions: A-CP HA Kit, ArthroVisc 40, Placebo; Device · Drug
Lead sponsor: Regen Lab SA; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Pediatric Pulmonary Hypertension
Interventions: Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more

Conditions: Parenting, Parent-Child Relations, Relationship, Marital, Relationship, Family, Relationships, Father-Child, Fathers
Interventions: Enhanced Saint Francis Fatherhood FIRE Program, Services as Usual Saint Francis Fatherhood FIRE Program; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage 2 Diastolic Hypertension
Interventions: nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 89
States / cities: Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more

Conditions: Macular Degeneration
Interventions: ranibizumab, verteporfin; Drug
Lead sponsor: Texas Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas

Conditions: Metastatic Liver Cancer
Interventions: SIRT, capecitabine; Radiation · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Search by objective public record fields.

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Facilitating Alcohol Screening and Treatment (FAST)

Improving Balance for Older Adults: Disseminating Tai Chi Fundamentals Through Community Organizations

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

rTMS Combined With BWSTT in Stroke With Body Weight Supported Treadmill Training (BWSTT) After Stroke

Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Comparative Evaluation of A-CP HA Kit, Hyaluronic Acid and Placebo for the Treatment of Knee Osteoarthritis

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Local Evaluation of the Saint Francis Ministries Fatherhood FIRE Program

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Ranibizumab and Reduced Fluence PDT for AMD

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver